FDG - A marker of tumour hypoxia? A comparison with [18F] fluoromisonidazole and pO2-polarography in metastatic head and neck cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 12, 2006, Pages 1426-1431

  Zimny, Michael ^a,c,d   Gagel, Bernd ^a   DiMartino, Ercole ^a   Hamacher, Kurt ^b   Coenen, Heinz H ^b   Westhofen, Martin ^a   Eble, Michael ^a   Buell, Ulrich ^a   Reinartz, Patrick ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c Klinikum Hanau   (Germany)

^d Nuklearmedizin   (Germany)

Author keywords

Fluorodeoxyglucose; Fluoromisonidazole; PO2 polarography; Positron emission tomography; Tumour hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE ANALYSIS; INTERMETHOD COMPARISON; OXYGEN TENSION; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY;

ANOXIA; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MISONIDAZOLE; NEOPLASM METASTASIS; OXYGEN; POLAROGRAPHY; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845352355     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0175-6     Document Type: Article

References (39)

1. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-257
2. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(Suppl 5):4-9
3. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117
4. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-648
5. 2 tension measurements. Cancer Res 1991;51:3316-3322
6. Mueller-Klieser W, Schlenger KH, Walenta S, Gross M, Karbach U, Hoeckel M, et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 1991;20(Suppl 1):21-28
7. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50
8. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24
9. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212
10. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-398
11. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-428
12. Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378-1383
13. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384-1391
14. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687-702
15. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523-1528
16. Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999;26:95-109
17. 18F]-2-fluoro-2′- deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-622
18. Kallinowski F, Brownell AL, Vaupel P, Brownell GL. Combined tissue oxygen tension measurement and positron emission tomography studies on glucose utilization in oncogene-transformed cell line tumour xenografts in nude mice. Br J Radiol 1991;64:350-359
19. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-1632
20. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-946
21. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545-553
22. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-2252
23. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005;46:675-682
24. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:601-609
25. Thill R, Neuerburg J, Fabry U, Cremerius U, Wagenknecht G, Hellwig D, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997;36:234-239
26. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results. Nuklearmedizin 1997;36:228-233
27. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704
28. 18F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-637
29. Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005;62:854-861
30. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-946
31. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170-175
32. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-472
33. Bos R, van der Hoeven JJ, van der Wall E, van der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387
34. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-S67
35. Lim JH, Lee ES, You HJ, Lee JW, Park JW, Chun YS. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004;23:9427-9431
36. 18F- fluoromisonidazole positron emission tomography. BJU Int 2005;96:540-546
37. 2 study. Cancer 2000;89:2018-2024
38. 2 histography in R3327-AT rodent tumors. Radiat Res 2000;154:439-446
39. 2. Acta Oncol 1997;36:183-189